-
Why NICE Recommendation Is Turning Point For PTC Therapeutics Shares
Monday, April 18, 2016 - 1:30pm | 414Read More...Oppenheimer said the recent recommendation from NICE for Translarna is a "turning point" for PTC Therapeutics, Inc. (NASDAQ: PTCT) shares, as it bodes well for the upcoming CHMP review. The Importance Of Translarna To PTC On Friday, shares of PTC Therapeutics surged more than 40 percent after it...
-
PTC Therapeutics Spikes 40% After Translarna Update In England
Friday, April 15, 2016 - 1:45pm | 364Read More...Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company that focuses on therapeutics that target post-transcriptional control processes, surged higher by more than 40 percent Friday afternoon. Investors and traders were reacting to the company's announcement that the...
-
Wall Street Really Blew It On PTC Therapeutics
Tuesday, March 1, 2016 - 2:37pm | 305Read More...It’s been about six weeks since Credit Suisse initiated coverage of PTC Therapeutics, Inc. (NASDAQ: PTCT) with an Outperform rating and $36 price target on the stock. Now, less than two months later, the stock is down more than 76 percent and trading at $5.70 per share. On February 23, PTC...
-
PTC Therapeutics: Oppenheimer Bull Cuts Target From $111 To $39; Jefferies Less Certain on Translarna
Tuesday, March 1, 2016 - 10:21am | 333Read More...Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) were down as much as 2 percent in the pre-market hours Tuesday following the U.S. FDA questioning the effectiveness of Translarna in nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC was notified that negative results from both Phase-2b and...
